טוען...
Farnesoid X Receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through down-regulation of HER2 expression
Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor α (ERα) positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatme...
שמור ב:
| הוצא לאור ב: | Oncogene |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4482257/ https://ncbi.nlm.nih.gov/pubmed/21499302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2011.124 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|